Treatments for RYR1-related disorders

Cochrane Database Syst Rev. 2024 Dec 10;12(12):CD014439. doi: 10.1002/14651858.CD014439.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective To analyse the benefits and harms of pharmacological or other interventions (e.g. special diet, exercise programme) compared with placebo or standard care for RYR1-related disorders, including both permanent myopathies and intermittent (episodic) presentations (exertional myalgia and rhabdomyolysis), with the aim to improve motor and respiratory function and/or to reduce the frequency of episodes, respectively. Secondary objectives To assess whether the interventions, compared with placebo or standard of care, change the outcome of RYR1-related diseases. To assess whether the interventions, compared with placebo or usual care, change the expression of the disease state in patients with RYR1-related diseases. To identify a set of standardised outcome tools to be used in future studies.

MeSH terms

  • Humans
  • Muscular Diseases* / genetics
  • Muscular Diseases* / therapy
  • Myalgia / therapy
  • Randomized Controlled Trials as Topic
  • Rhabdomyolysis* / therapy
  • Ryanodine Receptor Calcium Release Channel* / genetics
  • Systematic Reviews as Topic

Substances

  • Ryanodine Receptor Calcium Release Channel
  • RYR1 protein, human